Clinical Research Directory
Browse clinical research sites, groups, and studies.
Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score
Sponsor: Wuerzburg University Hospital
Summary
This study aims to evaluate the prevalence of Fabry Disease (FD) among a cohort of high risk patients with left ventricular hypertrophy (LVH) presenting at the University Hospital Würzburg over the last 20 years. Fabry disease is a rare disease that is known to be consistently underdiagnosed due to its largely variable symptoms. Considering that an early Fabry diagnosis is crucial for maximum benefit from therapies available, screening for Fabry patients can contribute to preventing development and worsening of symptoms in Fabry patients with LVH. In addition, a positive diagnosis in a family member opens the possibility to diagnose further family members in an earlier stage of the disease, therefore allowing treatment of symptoms and organ manifestations before they become irreversible.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2021-07-01
Completion Date
2024-10-01
Last Updated
2024-06-12
Healthy Volunteers
No
Conditions
Interventions
blood sampling (alpha-Galactosidase & LysoGb3)
A blood sample will be taken. Alpha-Galactosidase level and LysoGb3 will be measured. Amendment: Offering of genetic testing for fabry specific GLA-gene
Locations (1)
University Hospital Wuerzburg
Würzburg, Bavaria, Germany